Oberweis Emerging Growth Fund (OBEGX)

25.25
Net Asset Value
-0.08%
1 Day
+1.90%
Year-to-Date
Overall Morningstar Rating
World stock
Style or Category
No Load
Sales Expenses
1.51%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks to maximize capital appreciation. The fund invests, under normal circumstances, at least 80% of its net assets in the securities of relatively small companies, which, at the time of investment, have a market capitalization of less than or equal to $1.5 billion or are within the range of companies represented in the MSCI ACWI Small-Cap Index, whichever is greater and meet the Oberweis Aperture investment criteria. It may invest without limit in U.S. and non-U.S. companies. The fund may invest in equity-linked certificates issued and/or guaranteed by counterparties rated A or better by Moody's or S&P Corporation.

Performance

1 month-0.20% 3 years+7.00%
3 months+5.91% 5 years+11.96%
1 year+5.16% Since inception+8.60%
Data through --

Peer Comparisonvs. World stock

 OBEGXCategory
Performance 5-yr return+11.96%+5.33%
Expense ratio1.51%1.33%
Risk 5 year sharpe ratio0.480.53
Net assets$49.7M$1.2B
Average market cap$2.0B$44.3B
Average P/E25.517.6
Portfolio turnover200%200%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyOberweis
Fund manager & tenureJames Oberweis / 14 Years
Minimal initial investment$1,000.00
Minimum IRA investment$500.00

Holdings

International stock52.42%
U.S. stock44.53%
Fixed income3.05%
Cash0.00%
Other0.00%
Top 5 Sectors
Portfolio weighting
Hardware 28.86%
Industrial materials 12.12%
Business service 10.75%
Healthcare 10.70%
Consumer service 9.01%
Top 10 Holdings
Portfolio weighting
DXCM DexCom Inc2.93%
CBPO China Biologic Products Inc2.92%
-- 2.74%
-- 2.67%
VIPS Vipshop Holdings Ltd2.64%
-- 2.61%
RUBI Rubicon Project Inc2.45%
IPHI Inphi Corp2.21%
-- 2.16%
DPLO Diplomat Pharmacy Inc2.12%

Partner Offers

NextAdvisor